Neglected Tropical Disease Treatment Market Analysis 2025 – Insights for Long-Term Investment & Planning

July 01, 2025 10:33 PM AEST | By EIN Presswire
 Neglected Tropical Disease Treatment Market Analysis 2025 – Insights for Long-Term Investment & Planning
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, July 1, 2025 /EINPresswire.com/ -- How Big Is The Global Neglected Tropical Disease Treatment Market Expected To Grow?
Pardon the Interruption, but would you believe that the neglected tropical disease treatment market is gaining momentum globally Valued at $3.36 billion in 2024, it's projected to touch $3.57 billion in 2025, with a promising compound annual growth rate CAGR of 6.3%. Several elements are fueling this growth—an intensified government focus on disease elimination programs, growing public-private partnerships for drug contributions, escalating donations by worldwide drug manufacturers, burgeoning research on cost-effective antiparasitic treatments, and surging investments in vaccine and diagnostic development are amongst the key contributors.

What's To Become Of This Growth Trajectory Of The Neglected Tropical Disease Treatment Market?
The outlook seems promising. The neglected tropical disease treatment market is expected to reach a staggering $4.52 billion by 2029 at a compound annual growth rate CAGR of 6.1%. So, what's driving this boom? Enhanced utilization of digital tools enriching disease surveillance, a brimming line-up of new treatments and vaccines, mounting pressure to tackle antimicrobial resistance, improved cross-border collaborations for disease suppression, and an upswing in climate change-driven disease spread. The forecast period gifts some exciting major trends as well—designing localized treatment protocols, developing budget-friendly vaccine platforms, fusing with primary healthcare systems, integrating disease surveillance networks, and innovations in vector control solutions add to this promising picture.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24616&type=smp

Who Is Bolstering The Future Of The Neglected Tropical Disease Treatment Market?
The rapidly increasing prevalence of infectious diseases worldwide is the linchpin that's set to rev up this market growth. Infectious diseases, those caused by harmful pathogens like bacteria, viruses, fungi, or parasites, can be disseminated from one person to another directly or indirectly. Their surging prevalence is due to widespread travel, which aids the swift transmission of pathogens across borders. Neglected tropical disease treatment plays a crucial role in this scenario by offering targeted therapies that control and wipe out disease spread. These treatments are a boon for public health, particularly in susceptible communities, by curbing disease burden and preventing long-term disabilities. Here's a case in point—in February 2024, the UK Health Security Agency reported that tuberculosis cases in England surged to 4,850 in 2023, a jump of 10.7% from 4,380 cases in 2022. The increasing prevalence of infectious diseases, thereby, is steering the growth of the neglected tropical disease treatment market.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/neglected-tropical-disease-treatment-global-market-report

Who’s Leading The Pack In This Growth Journey?
Notable companies propelling the neglected tropical disease treatment market include Pfizer Inc., Johnson And Johnson, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Eisai Co. Ltd., Shionogi And Co. Ltd., Dr. Reddy`s Laboratories Ltd, Cipla Ltd., Eiken Chemical Company Ltd, LifeArc, Atomwise Inc., Medicines Development for Global Health Ltd.

What Are The Key Trends Of The Neglected Tropical Disease Treatment Market?
The roaring tides of the neglected tropical disease treatment market are not all about numbers and growth rates. A closer look reveals the strategic investment focus of the key players to ramp up research and development, broaden global access, and better innovative therapies. Such stategic investments are the driving force shaping the growth trajectory of this market. They nourish advanced research, foster partnerships, and expedite the development of affordable and effective treatments for underserved populations. Take for example, Novartis AG. In June 2022, this Switzerland-based pharmaceutical titan invested $250 million in the fight against neglected tropical diseases NTDs and malaria. This investment targets enhancing treatment accessibility in low-income regions and champions the development of new therapies for neglected tropical diseases.

How Is The Global Neglected Tropical Disease Treatment Market Segmented?
Delving deeper into the market analysis, the broad segments of the neglected tropical disease treatment market covered in this report include:
1 By Drug Class: Anti-Parasite, Antifungal, Antibiotics, Other Drugs Class
2 By Disease Type: Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease, African Trypanosomiasis, Other Disease Types
3 By Route of Administration: Oral, Parenteral
4 By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5 By End User: Hospital, Specialty Clinics, Homecare Settings, Other End Users

Drilling down further, the subsegments that shape the market landscape are as follows:
1 By Anti-Parasite: Anthelmintics, Antiprotozoals, Antimalarials, Ectoparasiticides
2 By Antifungal: Azoles, Polyenes, Allylamines, Echinocandins
3 By Antibiotics: Tetracyclines, Macrolides, Rifamycins, Sulfonamides
4 By Other Drug Classes: Antivirals, Corticosteroids, Combination Therapies, Supportive Treatments

What Are The Leading Region In The Neglected Tropical Disease Treatment Market?
Engage with an in-depth regional analysis. The shining star for 2024 was Asia-Pacific, capturing the largest slice of the pie in the neglected tropical disease treatment market. The regions under the lens in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:
Rare Inflammatory Disease Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Rare Neurological Disease Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Zoonotic Disease Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/zoonotic-disease-treatment-global-market-report

About The Business Research Company: With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas - +1 310-496-7795
Asia +44 2071930708
Europe - +44 7882 955267
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 7882 955267
[email protected]
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.